Fluoxetine inhibits the metabolism of tolterodine: Pharmacokinetic implications and proposed clinical relevance

British Journal of Clinical Pharmacology

Volumn 48, Issue 4, 1999, Pages 553-563

  Brynne, N ^a   Svanstrom C ^a   Aberg Wistedt A ^b   Hallen B ^a   Bertilsson, L ^c  

^a Pharmacia and Upjohn AB ^*  (Sweden)

^b ST GÖRAN S HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antimuscarinic; CYP2D6; CYP3A4; Drug interaction; Drug metabolism; PNU 200577; Tolterodine; Urinary incontinence

Indexed keywords

DRUG METABOLITE; FLUOXETINE; FONTEX; NORFLUOXETINE; TOLTERODINE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GENOTYPE; HEADACHE; HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PRIORITY JOURNAL;

BENZHYDRYL COMPOUNDS; CRESOLS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; HYDROXYLATION; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT DROPOUTS; PHENOTYPE; PHENYLPROPANOLAMINE; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0032869577     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00051.x     Document Type: Article

References (30)

1. 1 Rentzhog L, Stanton SL, Cardozo L, Fall M, Nelson E, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study. Br J Urol 1998; 81: 42-48.
2. 2 Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-810.
3. 3 Van Kerrebroeck PEVA, Amarenco G, Thüroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998; 17: 499-512.
4. 4 Nilvebrant L, Andersson K-E, Gillberg P-G, Stahl M, Sparf B. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207.
5. 5 Brynne N, Stahl MMS, Hallén B, Edlund PO, Palmér L, Gabrielsson J. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 287-295.
6. 6 Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 1998; 63: 529-539.
7. 7 Postlind H, Lindgren A, Andersson SHG. Tolterodine, a novel muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26: 289-293.
8. 8 Nilvebrant L, Gillberg P-G, Sparf B. Antimuscarinic potency and bladder selectivity of PNU 200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 169-172.
9. 9 Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-537.
10. 10 Påhlman I, Gozzi P. Protein binding of tolterodine and its major metaboltes in human and several animal species. Biopharm Drug Dispos 1999; 20: 91-99.
11. 11 Altamura AC, De Novellis F, Guercetti G, Invernizzi G, Percudani M, Montgomery SA. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res 1989; 9: 391-396.
12. 12 Altamura AC, Mauri MC. Aspects of treatment of elderly depression: the fluoxetine experience. In The Use of Fluoxetine in Clinical Practice, Vol. 183. eds. Freeman HL, London: Royal Society of Medicine Services, 1991: 53-59.
13. 13 Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481-508.
14. 14 Rosenthal J, Hemlock C, Hellerstein DJ, et al. A preliminary study of serotonergic antidepressants in treatment of dysthymia. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 933-941.
15. 15 Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-265.
16. 16 Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1992; 53: 401-409.
17. 17 Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72: 835-847.
18. 18 Thomas TM, Plymatt KR, Blannin J, Meade TW. Prevalence of urinary incontinence. Br Med J 1980; 281: 1243-1245.
19. 19 Palmér L, Andersson L, Andersson T, Stenberg U. Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography mass spectrometry. J Pharm Biomed Anal 1997; 16: 155-165.
20. 20 Björk H, Bengtsson F. A simple method for routine TDM of the SSRI fluoxetine and norfluoxetine in serum by HPLC. Eur J Clin Pharmacol 1997; 52(Suppl); A156.
21. 21 Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51: 12-17.
22. 22 Statistical Consultants Inc. PCNonlin and Nonlin84: Software for the statistical analysis of nonlinear models. Am Stat 1986; 40: 52.
23. 23 Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker 1982.
24. 24 Rowland M, Tozer TN. Clinical pharmacokinetics: Concepts and Applications, 3rd edn. Philadelphia: Williams & Wilkins 1995.
25. 25 Tozer T. Implications of altered plasma protein binding in disease states. In Pharmacokinetic basis for drug treatment, eds. Benet LZ, Massoud N, Gambertoglio JG, New York: Raven Press, 1984: 173-193.
26. 26 Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52: 479-486.
27. 27 Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991; 50: 10-15.
28. 28 Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992; 6: 752-758.
29. 29 Vahre A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-607.
30. 30 Brynne N, Forslund C, Hallén B, Gustafsson LL, Bertilsson L. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Exp Toxicol Pathol 1998; 50: 96.